MedTrace Logo

Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)

NCT00055146 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2009-04-17

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and effectiveness of ONTAK in previously treated patients with chronic lymphocytic leukemia (CLL)

Conditions

  • Leukemia, Lymphocytic, Chronic

Interventions

DRUG

ONTAK

Sponsors & Collaborators

  • Eisai Inc.

    lead INDUSTRY

Principal Investigators

  • Elyane Lombardy, M.D. · Ligand Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-03-31
Primary Completion
2006-03-31
Completion
2006-05-31

Countries

  • United States
  • Argentina
  • Australia
  • Brazil
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00055146 on ClinicalTrials.gov